Rare is less rare than one might think

This editorial asks, in the era of genomic profiling, aren’t most cancers biologically distinct, molecularly defined rare diseases rather than broad organ-based entities? Such framing could align clinical trial design, regulatory pathways, and drug-development incentives with the realities of precision oncology. | Nabhan, J Clin Oncol 2026